XML 21 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 29, 2023
Dec. 30, 2022
Current assets:    
Cash and cash equivalents $ 262,994 $ 501,195
Short-term investments 732,308 807,273
Trade receivables, net 237,407 214,784
Inventory 17,323 33,299
Prepaid expenses and other current assets 67,926 62,211
Total current assets 1,317,958 1,618,762
Long-term investments 728,717 756,731
Property and equipment, net 128,731 110,624
Deferred tax assets, net 361,145 231,110
Goodwill 63,684 63,684
Right-of-use assets and other 342,122 290,578
Total assets 2,942,357 3,071,489
Current liabilities:    
Accounts payable 33,768 32,667
Accrued compensation and benefits 93,325 77,158
Accrued clinical trial liabilities 71,615 65,072
Rebates and fees due to customers 59,619 50,350
Accrued collaboration liabilities 27,533 20,188
Other current liabilities 108,417 78,924
Total current liabilities 394,277 324,359
Long-term portion of operating lease liabilities 189,944 190,170
Other long-term liabilities 94,224 68,533
Total liabilities 678,445 583,062
Commitments and contingencies (Note 11)
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 302,793 and 323,951 at December 31, 2023 and 2022, respectively 303 324
Additional paid-in capital 2,440,710 2,536,849
Accumulated other comprehensive loss (3,750) (14,521)
Accumulated deficit (173,351) (34,225)
Total stockholders’ equity 2,263,912 2,488,427
Total liabilities and stockholders’ equity $ 2,942,357 $ 3,071,489